Floatz logo

Vistide

Cytomegalovirus Retinitis

National Center for Research Resources (NCRR)Small moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cytomegalovirus Retinitis cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Vistide is also rated in:

HIV infectious diseaseDormant
BB
Indicative · Phase 4
65 / 100
View asset →
AIDSDormant
B
Indicative · Phase 2
57 / 100
View asset →
precancerous conditionDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →